Adma Biologics (ADMA) 9.13 $ADMA
ADMA Biologics Announces Data to be Presented at the Clinical Immunology Society 2015 Annual Meeting
GlobeNewswire - Tue Apr 07, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its poster titled "Analysis of Specific Antibody Levels in PIDD Patients Enrolled in a Pivotal Trial with an IVIG Containing High Titer Neutralizing Antibody to RSV," will be presented at the upcoming Clinical Immunology Society 2015 Annual Meeting, being held April 9-12, 2015 in Houston, Texas.
ADMA: 9.13 (-0.26)
Insider Trading Alert - CSGS, KCG And ADMA Traded By Insiders
at The Street - Tue Mar 24, 10:45AM CDT
Stocks with insider trader activity include CSGS, KCG and ADMA
KCG: 12.28 (-0.07), ADMA: 9.13 (-0.26), CSGS: 30.63 (+0.28)
InsiderInsights.com Daily Round Up 3/18/15: DO, ASPS, CGIX, ADMA
InsiderInsights - at Seeking Alpha - Thu Mar 19, 11:55AM CDT
MPW: 14.93 (+0.05), SSNC: 62.93 (+0.89), SANW: 4.71 (+0.16), ADMA: 9.13 (-0.26), ASPS: 20.53 (+1.62), MMI: 38.60 (-0.27), PSA: 193.69 (-0.44), ENOC: 11.63 (+0.23), PCLN: 1,189.50 (+3.50), CGIX: 9.29 (+0.51), FDS: 158.55 (-2.49), GGP: 28.81 (-0.14), NEE: 104.90 (+0.89), DO: 29.61 (-0.85), RXDX: 10.55 (-0.20), DYN: 31.31 (+0.46), TCB: 15.74 (+0.04), TWTR: 51.94 (-0.23), RGS: 17.27 (+0.17)
ADMA Bio closes equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 9:53AM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
GlobeNewswire - Wed Mar 18, 9:30AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 1,225,000 shares of common stock at a public offering price of $8.00 per share, as well as 183,750 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.
ADMA: 9.13 (-0.26)
ADMA Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:39AM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Mar 13, 8:21AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,225,000 shares of common stock at a public offering price of $8.00 per share, resulting in gross proceeds of approximately $9,800,000.
ADMA: 9.13 (-0.26)
ADMA Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 6:14PM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Mar 12, 3:32PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMA: 9.13 (-0.26)
Adma Biologics reports 4Q loss
Automated Insights - Mon Mar 09, 6:58PM CDT
RAMSEY, N.J. (AP) _ Adma Biologics Inc. (ADMA) on Monday reported a loss of $3.6 million in its fourth quarter.
ADMA: 9.13 (-0.26)
ADMA Biologics reports FY'14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 4:45PM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Reports Year End 2014 Results and Upcoming Milestones
GlobeNewswire - Mon Mar 09, 4:30PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the year ended December 31, 2014, in addition to 2014 accomplishments and anticipated milestones for 2015.
ADMA: 9.13 (-0.26)
ADMA Bio's lead product candidate successful in Phase 3 study
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 10:47AM CST
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Data to be Presented at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
GlobeNewswire - Tue Feb 17, 7:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its abstract titled "Pharmacokinetics of RI-002, an Investigational IGIV Preparation" will be presented at the upcoming 2015 American Academy of Allergy Asthma & Immunology (AAAAI), annual meeting, being held February 19-24, 2015 in Houston, Texas.
ADMA: 9.13 (-0.26)
ADMA Biologics (ADMA) Jumps: Stock Rises 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:11AM CST
ADMA Biologics, Inc. (ADMA) was a big mover last session, as the company saw its shares rise slightly over 7% on the day.
ADMA: 9.13 (-0.26), AFFX: 12.85 (+0.22)
ADMA Biologics Receives $5M Tranche From Hercules Technology Growth Capital
GlobeNewswire - Mon Dec 15, 7:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. (NYSE:HTGC), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets. The $5 million was based upon ADMA achieving clinical endpoints of a Phase III clinical study of RI-002 as a treatment for Primary Immunodeficiency Disease (PIDD), under its existing loan and security agreement.
HTGC: 13.75 (+0.12), ADMA: 9.13 (-0.26)
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 425.65 (-0.98), ADMA: 9.13 (-0.26), ANIP: 68.23 (-1.34), AMGN: 163.38 (+1.89)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 04, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RDUS: 43.18 (-1.10), IMDZ: 24.65 (+0.16), ADMA: 9.13 (-0.26), MCEP: 5.81 (-0.01), SCYX: 9.11 (-0.24), BOBE: 46.13 (-0.58), HCCI: 13.48 (+0.14), TCCO: 4.43 (unch), STRZB: 34.88 (+0.19), STRZA: 35.91 (+0.48)
ADMA Biologics Slumps: ADMA Tanks 11% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:53AM CST
ADMA Biologics has been witnessing a positive trend in its current year estimate revision and its share price has been falling for past few days
BIIB: 425.65 (-0.98), ADMA: 9.13 (-0.26), ANIP: 68.23 (-1.34), AFFX: 12.85 (+0.22)
ADMA Biologics Announces Data to be Presented at the Clinical Immunology Society 2015 Annual Meeting
GlobeNewswire - Tue Apr 07, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its poster titled "Analysis of Specific Antibody Levels in PIDD Patients Enrolled in a Pivotal Trial with an IVIG Containing High Titer Neutralizing Antibody to RSV," will be presented at the upcoming Clinical Immunology Society 2015 Annual Meeting, being held April 9-12, 2015 in Houston, Texas.
ADMA: 9.13 (-0.26)
Insider Trading Alert - CSGS, KCG And ADMA Traded By Insiders
at The Street - Tue Mar 24, 10:45AM CDT
Stocks with insider trader activity include CSGS, KCG and ADMA
KCG: 12.28 (-0.07), ADMA: 9.13 (-0.26), CSGS: 30.63 (+0.28)
InsiderInsights.com Daily Round Up 3/18/15: DO, ASPS, CGIX, ADMA
InsiderInsights - at Seeking Alpha - Thu Mar 19, 11:55AM CDT
MPW: 14.93 (+0.05), SSNC: 62.93 (+0.89), SANW: 4.71 (+0.16), ADMA: 9.13 (-0.26), ASPS: 20.53 (+1.62), MMI: 38.60 (-0.27), PSA: 193.69 (-0.44), ENOC: 11.63 (+0.23), PCLN: 1,189.50 (+3.50), CGIX: 9.29 (+0.51), FDS: 158.55 (-2.49), GGP: 28.81 (-0.14), NEE: 104.90 (+0.89), DO: 29.61 (-0.85), RXDX: 10.55 (-0.20), DYN: 31.31 (+0.46), TCB: 15.74 (+0.04), TWTR: 51.94 (-0.23), RGS: 17.27 (+0.17)
ADMA Bio closes equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 9:53AM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
GlobeNewswire - Wed Mar 18, 9:30AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 1,225,000 shares of common stock at a public offering price of $8.00 per share, as well as 183,750 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.
ADMA: 9.13 (-0.26)
ADMA Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:39AM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Mar 13, 8:21AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,225,000 shares of common stock at a public offering price of $8.00 per share, resulting in gross proceeds of approximately $9,800,000.
ADMA: 9.13 (-0.26)
ADMA Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 6:14PM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Mar 12, 3:32PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMA: 9.13 (-0.26)
Adma Biologics reports 4Q loss
Automated Insights - Mon Mar 09, 6:58PM CDT
RAMSEY, N.J. (AP) _ Adma Biologics Inc. (ADMA) on Monday reported a loss of $3.6 million in its fourth quarter.
ADMA: 9.13 (-0.26)
ADMA Biologics reports FY'14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 4:45PM CDT
ADMA: 9.13 (-0.26)
ADMA Biologics Reports Year End 2014 Results and Upcoming Milestones
GlobeNewswire - Mon Mar 09, 4:30PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the year ended December 31, 2014, in addition to 2014 accomplishments and anticipated milestones for 2015.
ADMA: 9.13 (-0.26)
ADMA Bio's lead product candidate successful in Phase 3 study
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 10:47AM CST
ADMA: 9.13 (-0.26)
ADMA Biologics Announces Data to be Presented at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
GlobeNewswire - Tue Feb 17, 7:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its abstract titled "Pharmacokinetics of RI-002, an Investigational IGIV Preparation" will be presented at the upcoming 2015 American Academy of Allergy Asthma & Immunology (AAAAI), annual meeting, being held February 19-24, 2015 in Houston, Texas.
ADMA: 9.13 (-0.26)
ADMA Biologics (ADMA) Jumps: Stock Rises 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:11AM CST
ADMA Biologics, Inc. (ADMA) was a big mover last session, as the company saw its shares rise slightly over 7% on the day.
ADMA: 9.13 (-0.26), AFFX: 12.85 (+0.22)
ADMA Biologics Receives $5M Tranche From Hercules Technology Growth Capital
GlobeNewswire - Mon Dec 15, 7:08AM CST
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. (NYSE:HTGC), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets. The $5 million was based upon ADMA achieving clinical endpoints of a Phase III clinical study of RI-002 as a treatment for Primary Immunodeficiency Disease (PIDD), under its existing loan and security agreement.
HTGC: 13.75 (+0.12), ADMA: 9.13 (-0.26)
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 425.65 (-0.98), ADMA: 9.13 (-0.26), ANIP: 68.23 (-1.34), AMGN: 163.38 (+1.89)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 04, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RDUS: 43.18 (-1.10), IMDZ: 24.65 (+0.16), ADMA: 9.13 (-0.26), MCEP: 5.81 (-0.01), SCYX: 9.11 (-0.24), BOBE: 46.13 (-0.58), HCCI: 13.48 (+0.14), TCCO: 4.43 (unch), STRZB: 34.88 (+0.19), STRZA: 35.91 (+0.48)
ADMA Biologics Slumps: ADMA Tanks 11% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:53AM CST
ADMA Biologics has been witnessing a positive trend in its current year estimate revision and its share price has been falling for past few days
BIIB: 425.65 (-0.98), ADMA: 9.13 (-0.26), ANIP: 68.23 (-1.34), AFFX: 12.85 (+0.22)
